In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on OHR Pharmaceutical (NASDAQ:OHRP) with a $34 price target, …
In a research report released today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Chimerix (NASDAQ:CMRX) with a $33 price target, as preliminary data from …
In a research report published today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a $41 price target. …
In a research report published today, analyst Jonathan Aschoff of Brean Capital maintained a Buy rating on Pacira (NASDAQ:PCRX) with a $111 price target, which represents a …
In a research report published today, Brean Capital analyst Jonathan Aschoff reaffirmed a Sell rating on Rockwell Medical (NASDAQ:RMTI) with a $4.00 price target, which represents …
In a research report published today to investors, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a $16 …
In a research note published today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, as the …
In a research published today, Brean Capital analyst Jonathan Aschoff downgraded shares of Endocyte (NASDAQ:ECYT) from a Buy to a Hold rating, on …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a $16 price …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a price target …
